Revvity, 62KBSAKAF, HTRF Kinase-Streptavidin mAb Eu-Conjugate, 1,000 Assay Points

Overview
The ​Streptavidin was labeled with Eu crypate. Biotin binds to Streptavidin with high affinity (Ka=10^15 M-1). This binding is rapid and stable, making it an ideal choice for use in the biochemical HTRF Kinase Binding platform.​
HTRF assays offer many advantages over other technologies:

Homogeneous add-and-read format
No wash steps
Low background
Straightforward miniaturization from 96- or 384-well microplates to high density assay formats such as 384-well low volume and 1536-well plates
Stable signal, providing flexibility in time of readout or size of assays
How it works
Kd determination assay principle
​The binding of the tracers is detected in a sandwich assay format using Streptavidin labeled with Europium Cryptate (donor), which binds to the N-terminal biotinylated-Kinase, and a red fluorescent tracer labelled with d2 (acceptor). The detection principle is based on HTRF® technology. The HTRF ratio (665/620) will increase upon the addition of more of the tracer, and will saturate depending on the dissociation constant (Kd) of the tracer to the N-terminal biotinylated-Kinase.

 
Kd determination assay protocol
Saturation binding experiments on the three tracers (i.e. Staurosporine-Red, Dasatinib-Red, and Sunitinib-Red) can be run in 96- or 384-well plates (20 µL final volume). First, a dilution series of tracer ranging between 0 and 1 µM in the Kinase Binding Buffer is prepared in a 96-well non-binding plate. NExt, 5 µL of Kinase Binding Buffer are dispensed into the final 96- or 384-well plate. Then 5 µL of N-terminal biotinylated-Kinase are added, followed by 5 µL of Streptavidin Eu-cryptate. Finally 5 µL of the red tracer solution are added. The HTRF ratio is measured after 1 H of incubation.

 
IC50/Ki determination assay principle
Principle of HTRF® Kinase binding assay (IC50/Ki-determination). The binding of the tracers is detected in a sandwich assay format using Streptavidin labeled with Europium Cryptate (donor), which binds to the tagged Kinase, and a red fluorescent tracer labelled with d2 (acceptor). The detection principle is based on HTRF® technology. The HTRF ratio (665/620) will increase upon the addition of more of the tracer, and will saturate depending on the dissociation constant (Kd ) of the tracer to the tagged kinase. When an inhibitor of the kinase is added, the tracer will be displaced and the HTRF signal will disappear, depending on the dose.

 
IC50/Ki determination assay protocol
​​Pharmacological evaluation of inhibitors of interest can be run in 96- or 384-well plates. First, a dilution series of inhibitor ranging between 40 µM and 0.23 nM is prepared, and 5 µL of each concentration are dispensed into the plate. Next, 5 µL of tagged-Kinase are added, followed by 5 µL of Streptavidin Eu-cryptate. Finally, 5 µL of tracer solution are added, prepared at 4x the final concentration. The HTRF ratio is measured after 1H of incubation. Analyses of the data give typical dose response curves ranging between 10 µM and 56 pM, enabling an evaluation of the IC50/Ki values for the inhibitor of interest. Application-Biochemical Enzymatic Assay
Brand-HTRF
Detection Modality-HTRF
Product Group-Fluorescent Reagent
Shipping Conditions-Shipped in Dry Ice
Target Class-Kinases
Technology-TR-FRET
Therapeutic Area-Metabolism/Diabetes Neuroscience Oncology & Inflammation
Unit Size-1,000 assay points